Novo Nordisk A/S
NONOFOTCHealthcare● Active
$41.92
$-1.44(-3.33%)
Market Cap$186.2B
P/E Ratio—
52W High$82.5
52W Low$34
Novo Nordisk A/S (NONOF) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
NONOF · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$1.02
Est. $0.93 · +10.3%
Revenue
$10.80B
Est. $10.74B · +0.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS✓ 2-Quarter EPS Beat Streak
NONOF reports quarterly as a OTC-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.58B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.58B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $0.81 | — | — | — | $11.10B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $0.93 | $1.02 | +10.3% | $10.80B | $10.74B | +0.6% |
| ▲ Q1 FY2026 | Feb 3, 2026 | $0.92 | $0.95 | +2.8% | $12.42B | $12.07B | +2.9% |
| ▼ Q4 FY2025 | Nov 5, 2025 | $0.77 | $0.71 | -7.9% | $11.78B | $12.37B | -4.8% |
| — Q3 FY2025 | Aug 6, 2025 | $0.94 | $0.94 | +0.5% | $12.13B | $12.30B | -1.4% |
| ▲ Q2 FY2025 | May 7, 2025 | $0.89 | $0.96 | +8.6% | $11.49B | $11.96B | -3.9% |
| ▲ Q1 FY2025 | Feb 5, 2025 | $0.83 | $0.88 | +5.9% | $11.86B | $11.09B | +6.9% |
| ▲ Q4 FY2024 | Nov 6, 2024 | $0.90 | $0.92 | +2.5% | $10.68B | $10.76B | -0.8% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$0.81
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$1.02
EPS Est.
$0.93
EPS Surpr.
+10.3%
Revenue
$10.80B
Q1 FY2026
Feb 3, 2026Beat
EPS Actual
$0.95
EPS Est.
$0.92
EPS Surpr.
+2.8%
Revenue
$12.42B
Q4 FY2025
Nov 5, 2025Miss
EPS Actual
$0.71
EPS Est.
$0.77
EPS Surpr.
-7.9%
Revenue
$11.78B
Q3 FY2025
Aug 6, 2025
EPS Actual
$0.94
EPS Est.
$0.94
EPS Surpr.
+0.5%
Revenue
$12.13B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$0.96
EPS Est.
$0.89
EPS Surpr.
+8.6%
Revenue
$11.49B
Q1 FY2025
Feb 5, 2025Beat
EPS Actual
$0.88
EPS Est.
$0.83
EPS Surpr.
+5.9%
Revenue
$11.86B
Q4 FY2024
Nov 6, 2024Beat
EPS Actual
$0.92
EPS Est.
$0.90
EPS Surpr.
+2.5%
Revenue
$10.68B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $4.94 | $5.15 | $5.52 | 1 |
| Q3 FY2027 | $5.33 | $5.56 | $5.96 | 1 |
| Q2 FY2027 | $5.52 | $5.77 | $6.17 | 1 |
| Q1 FY2027 | $5.75 | $6.01 | $6.43 | 1 |
| Q4 FY2026 | $4.45 | $4.64 | $4.97 | 1 |
| Q3 FY2026 | $4.80 | $5.01 | $5.36 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $79.4B | $82.0B | $86.5B | 4 |
| Q3 FY2027 | $75.1B | $77.6B | $81.8B | 5 |
| Q2 FY2027 | $75.8B | $78.4B | $82.6B | 4 |
| Q1 FY2027 | $74.3B | $76.8B | $81.0B | 4 |
| Q4 FY2026 | $72.3B | $74.7B | $78.7B | 8 |
| Q3 FY2026 | $69.2B | $71.7B | $77.3B | 9 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +10.3% | $44.70 | $46.02 | +2.95% |
| ▲ Q1 FY2026 | Feb 3, 2026 | +2.8% | $59.54 | $50.00 | -16.02% |
| ▼ Q4 FY2025 | Nov 5, 2025 | -7.9% | $48.00 | $49.25 | +2.60% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +0.5% | $47.64 | $45.50 | -4.49% |
| ▲ Q2 FY2025 | May 7, 2025 | +8.6% | $66.23 | $66.00 | -0.35% |
| ▲ Q1 FY2025 | Feb 5, 2025 | +5.9% | $83.61 | $85.45 | +2.20% |
| ▲ Q4 FY2024 | Nov 6, 2024 | +2.5% | $106.21 | $110.60 | +4.13% |
| ▼ Q3 FY2024 | Aug 7, 2024 | -7.0% | $128.84 | $119.50 | -7.25% |
Q2 FY2026+2.95%
Report Date
May 6, 2026
EPS Beat/Miss
+10.3%
Price Before
$44.70
Price After
$46.02
Q1 FY2026-16.02%
Report Date
Feb 3, 2026
EPS Beat/Miss
+2.8%
Price Before
$59.54
Price After
$50.00
Q4 FY2025+2.60%
Report Date
Nov 5, 2025
EPS Beat/Miss
-7.9%
Price Before
$48.00
Price After
$49.25
Q3 FY2025-4.49%
Report Date
Aug 6, 2025
EPS Beat/Miss
+0.5%
Price Before
$47.64
Price After
$45.50
Q2 FY2025-0.35%
Report Date
May 7, 2025
EPS Beat/Miss
+8.6%
Price Before
$66.23
Price After
$66.00
Q1 FY2025+2.20%
Report Date
Feb 5, 2025
EPS Beat/Miss
+5.9%
Price Before
$83.61
Price After
$85.45
Q4 FY2024+4.13%
Report Date
Nov 6, 2024
EPS Beat/Miss
+2.5%
Price Before
$106.21
Price After
$110.60
Q3 FY2024-7.25%
Report Date
Aug 7, 2024
EPS Beat/Miss
-7.0%
Price Before
$128.84
Price After
$119.50
Avg Beat Reaction-1.93%
Avg Miss Reaction-2.33%
Beat Rate6 / 8 quarters
Largest Move-16.02% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: NONOF ends December
Novo Nordisk A/S (NONOF) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $1.02 — beating the analyst consensus of $0.93 by +10.3%. NONOF has beaten EPS estimates for 2 consecutive quarters. The next NONOF earnings date is expected around September 1, 2026.
Each quarter, investors track NONOF earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. NONOF revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
NONOF's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
NONOF earnings · 5 questionsNovo Nordisk A/S's next earnings report is expected around September 1, 2026. NONOF typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; NONOF historically reports after market close (AMC).
NONOF earnings datewhen is NONOF earningsNONOF next earnings datewhen does NONOF report earningsNONOF earnings calendar
▸ Source: FMP · Novo Nordisk A/S SEC filings · US GAAP · Novo Nordisk A/S SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026